Anti-Mullerian hormone is the test almost every fertility work-up starts with, and the one most people misread. Here is the real range at every age, and the part the charts leave out: what your number actually predicts, and what it does not.
AMH measures roughly how many eggs you have left, not their quality and not your chance of a baby. It falls with age: median AMH is about 2.5 ng/mL at 30, 1.4 at 35, and 0.5 at 40, dropping below the 1.2 ng/mL diminished-reserve line by about age 36. But the normal range at every age is wide, so a single number means little on its own.
One thing to fix before you read your result: AMH assays are not standardized, and a chart made on one assay does not transfer to another. The numbers below come from one large cohort on one assay, shown to give you the shape and the spread. Your own lab's reference range is the one that applies to your blood.
Median and the middle 50% of women at each age. The spread is the point: there is no single normal number, only a range you read your own result against.
The bar spans the middle 50% of women at each age (25th to 75th percentile); the solid mark is the median. The faint vertical line is the 1.2 ng/mL diminished-reserve threshold. Values are from a 22,920-woman cohort measured on the Beckman Access assay. A different assay reports different numbers, so read your own result against your own lab's reference range, not this chart alone.
| Age | Median (ng/mL) | Middle 50% (ng/mL) | Median (pmol/L) |
|---|---|---|---|
| 25 | 3.3 | 1.9 to 5.7 | 23.6 |
| 30 | 2.5 | 1.2 to 4.3 | 17.8 |
| 35 | 1.4 | 0.5 to 2.9 | 10 |
| 40 | 0.5 | 0.2 to 1.3 | 3.6 |
| 45 | 0.1 | 0.05 to 0.3 | 0.7 |
Source: Aslan et al., age-stratified AMH nomogram (22,920 women), Front Endocrinol 2025. The same decline is documented in US women by Seifer et al., age-specific serum AMH for 17,120 US women, Fertil Steril 2011.
AMH is sold as a fertility score. It is not one. It is a good estimate of egg quantity and IVF response, and a poor predictor of whether you will have a baby.
The evidence for the second column is strong. A prospective cohort of women trying to conceive found low ovarian-reserve markers did not predict lower natural fertility, and both ACOG and ASRM advise against using AMH as a general fertility test. It earns its place in an IVF work-up because it predicts egg yield, which is a planning number, not a prognosis.
Where AMH genuinely changes decisions: the dose, the expected egg count, and sometimes the number of cycles you should budget for.
Points to fewer eggs per retrieval, so a clinic may use a higher stimulation dose and you may need to budget for more than one cycle to bank enough embryos. It does not lower the success of each good embryo, which still tracks age. If retrievals repeatedly yield very few eggs, that is when donor-egg IVF enters the conversation. See how cycle count moves the total on the cost calculator.
Usually means a strong response and more eggs, common with PCOS, but it also flags a higher risk of ovarian hyperstimulation, so the dose is often kept deliberately lower. More eggs is not the same as more babies: what carries a cycle is age and embryo quality, which is why the live-birth rates by age matter more than the egg count. Planning to preserve reserve early? See egg freezing.
AMH rarely travels alone. These are the other markers a fertility work-up uses, what each adds, and where each falls short.
Interpretation follows ASRM Practice Committee, Testing and interpreting measures of ovarian reserve (2020).
There is no single normal AMH: the range at every age is wide, and a result anywhere inside it is unremarkable. In a cohort of 22,920 women, the median was about 2.5 ng/mL at age 30 (middle 50% 1.2 to 4.3), 1.4 ng/mL at 35 (0.5 to 2.9), and 0.5 ng/mL at 40 (0.2 to 1.3). AMH assays are not standardized, so a different lab can report a different number for the same blood. Compare your result to your own lab's reference range, not to a chart from a different assay.
Not on its own. AMH estimates how many eggs remain, not their quality and not your odds of conceiving. A prospective study of 981 women who were not already struggling to conceive (Steiner, JAMA 2017) found that women with low ovarian-reserve markers were no less likely to get pregnant than women with normal ones. A low AMH does mean an IVF cycle is likely to collect fewer eggs, which can matter for treatment planning, but many women with a low AMH conceive, especially when they are younger.
No. AMH reflects egg quantity, or ovarian reserve. Egg quality falls with age largely independently of AMH, so a 30-year-old with a low AMH usually still has age-appropriate egg quality, while a 42-year-old with a normal-looking AMH still has the egg quality of a 42-year-old. This is the most common AMH misunderstanding, and it is why age remains the strongest single predictor of an IVF live birth, not AMH.
There is no cutoff below which IVF is refused, and specialty guidance (ASRM) says ovarian-reserve tests should not be used to deny treatment. AMH is used to set the drug dose and to set expectations for how many eggs a cycle will yield, not to decide whether to treat. A very low AMH points toward fewer eggs per cycle, and therefore sometimes more cycles or a conversation about donor eggs; a very high AMH (common in PCOS) flags a higher risk of over-response. Below about 1.2 ng/mL is often labelled diminished reserve, a planning threshold, not a verdict.
US labs report AMH in ng/mL; many labs elsewhere use pmol/L. To convert, multiply ng/mL by 7.14. So a median of 2.5 ng/mL at age 30 is about 17.8 pmol/L, and the 1.2 ng/mL diminished-reserve threshold is about 8.6 pmol/L. Always check which unit your report uses before comparing it to any chart.
Only loosely. AMH declines toward menopause on average, and a very low value in your forties is consistent with menopause approaching, but AMH cannot pin an individual's date. It is a population signal, not a personal countdown, which is why ACOG advises against using AMH as a general fertility or menopause-timing test in women who are not seeking fertility care.